Voreloxin - Sunesis Announces Data From Phase 2 Clinical Program of Voreloxin in Acute Myeloid Leukemia Support Phase 3 Trial in Relapsed or Refractory Patients - plus Ovarian Cancer

"Responses to single agent voreloxin observed in women with ovarian cancer for whom multiple prior therapies have failed, including some for whom both platinum-based chemotherapy and Doxil(R) had failed, are promising," said Hal Hirte (medical oncologist), M.D., Associate Professor, McMaster University, Department of Oncology and Chief of Oncology, Juravinski Cancer Centre at Hamilton Health Sciences (Ontario, Canada) and an investigator for the Phase 2 clinical trial. "These data warrant further investigation of voreloxin in this vastly underserved patient population, both in this later stage, salvage setting and in earlier lines of therapy."

financial news: Abstracts Highlighting Sunesis' Phase 2 Voreloxin Data Accepted for Presentation at 2010 ASCO Meeting

The presentations include an oral presentation of final data from the Company's Phase 2 trial of voreloxin in ovarian cancer....